GenSight Biologics: Goldman Sachs falls below 5% threshold

(CercleFinance.com) - On August 27, Goldman Sachs Group declared to the AMF that it had fallen below the thresholds of 5% of the capital and voting rights in GenSight Biologics, as a result of an off-market sale of shares to which the trading exemption applies.


The US investment bank no longer holds any GenSight shares within the meaning of Article 223-13 I, 2° of the General Regulations. At the same time, Goldman Sachs International individually crossed downwards the same thresholds.

Copyright (c) 2024 CercleFinance.com. All rights reserved.